BACKGROUND Efforts to treat relapsed medulloblastoma patients with immune checkpoint
inhibitors aim to enhance T-cell recognition and elimination of tumor cells. However …

Purpose: Despite significant strides in the identification and characterization of potential
therapeutic targets for medulloblastoma, the role of the immune system and its interplay with …

Background Immune checkpoint inhibitors (ICIs) can overcome the ability of tumor cells to
evade the immune system. However, current FDA-approved ICIs have been unsuccessful in …

Background Medulloblastoma, the most common embryonal brain tumor of childhood, has a
cold tumor immune microenvironment, harboring low lymphocytic infiltration and a paucity of …

Immune checkpoint therapy has resulted in minimal clinical response in many pediatric
cancers. We sought to understand the influence of immune checkpoint inhibition using anti …

Medulloblastoma (MB) is the most common pediatric brain tumor with few reports of
successful immunologic targeting. We have recently demonstrated the immune tumor …

VISTA Emerges as a Promising Immunotherapy Target in Cancer NEWS All NewsFDA BriefsOncology
IconsSpecial ReportsVoices from the Field CONFERENCES Conference CoverageConference …

[Purpose] V-domain Ig suppressor of T-cell activation (VISTA) is a novel immune checkpoint
molecule that regulate T-cell activation. VISTA is expressed on both T cells and antigen …

PD-L1 blockade has shown great success in the rejection of specific PD-L1+ tumor-types
within various tissues. Blocking PD-L1 interactions with PD-1 molecules expressed on …

The immunoglobulin (Ig) superfamily consists of many critical immune regulators, including
the B7 family ligands and receptors. In this study, we identify a novel and structurally distinct …